Drug Profile
Interleukin-1 receptor - Affymax
Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Interleukin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 14 Dec 2000 No-Development-Reported for Postmenopausal osteoporosis in USA (Injection)
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 02 Oct 1998 Investigation in Postmenopausal osteoporosis in USA (Injection)